A Phase 2 interventional study of 17-β estradiol transdermal patches and Placebo Patch in Eating Disorders and Hypoestrogenemia, sponsored by Massachusetts General Hospital. Completed at 1 site in United States. Open to female participants aged 14 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Massachusetts General Hospital · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Feeding and Eating Disorders by Massachusetts General Hospital — 1 open to participants now, 2 under way, none of them phase 3. Feeding and Eating Disorders · Massachusetts General Hospital.
Among the 10 studies in Feeding and Eating Disorders by Massachusetts General Hospital, this one is the only one that started in 2019, is one of 4 in phase 2, and was the 8th registered.
645 studies on the registry are indexed under Feeding and Eating Disorders; 151 are open to participants now.
Browse Feeding and Eating Disorders studies →1 of the 10 studies in Feeding and Eating Disorders by Massachusetts General Hospital is open now, in 1 country. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 99 Feeding and Eating Disorders studies recruiting now, 31 (31%) set no upper age limit and 66 (67%) stop at 75 or younger; 45 take children under 18; 20 take healthy volunteers.
This study: 14 Years to 35 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 2
First in 2003; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 122 is above the median of 71 across 452 interventional studies indexed under Feeding and Eating Disorders.
Median enrollment 75 across the 9 interventional studies, 64 across the 1 observational. Of the 8 that completed or were terminated, 5 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.
Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.
2 of the studies in Feeding and Eating Disorders by Massachusetts General Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01075672Massachusetts General HospitalOutcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals | 2027-01 |
| NCT05587127Massachusetts General HospitalExposure-Based CBT for Avoidant/Restrictive Food Intake in Functional Dyspepsia | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies in Feeding and Eating Disorders by Massachusetts General Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized, double blind, placebo-controlled study of the effects of transdermal estradiol versus placebo on cognitive flexibility, reward processing, and eating disorder pathology in hypoestrogenemic female adolescents and young adults (ages 14-35 years) with an eating disorder characterized by extreme dietary restriction and/or excessive exercise. Subjects will be randomized 1:1 to 12 weeks of transdermal estradiol with cyclic progesterone or placebo patches and cyclic placebo pills. Study visits include a screening visit to determine eligibility and visits at baseline, 8 weeks, and 12 weeks. Study procedures comprise behavioral, neuroimaging, and endocrine assessments.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: 17-β estradiol transdermal patches · Drug: Micronized progesterone 200 MG
Drug: Placebo Patch · Other: Placebo Pill.
17-β estradiol transdermal patches (100 mcg 17-β estradiol/day)
Placebo patch
Cyclic progesterone (200 mg micronized progesterone daily for 12 days every month)- administered to those randomized to the transdermal estradiol patch for endometrial protection
Administered to those receiving the placebo patch to maintain blinding
Change in inhibition-switching performance on the Delis-Kaplan Executive Function System Color-Word Interference Test (D-KEFS CWIT) with 17-β estradiol versus placebo
The Inhibition-Switching component of the D-KEFS CWIT simultaneously assesses verbal inhibition (suppressing the automatic urge to read the text) and cognitive flexibility/set-shifting (alternating rules on demand). Participants name the color of words representing colors printed in dissonant ink colors (e.g., the word "blue" in red ink). However, if words are framed by a box, they will be instructed to read the word instead. Within-condition scores are calculated by extracting two types of data: completion time and error metrics. The raw time is converted into an age-adjusted scaled score based on national normative data (Mean 10, SD 3). Uncorrected and self-corrected errors are tallied; total error counts are converted to a cumulative scaled score (Mean 10, SD 3). Total scaled scores range from 1-19 (0.1-99.9th percentile), with lower scores indicating clinically significant impairment and higher scores indicating superior performance.
Time frame: Baseline to 8 weeks
Change in Temporal Experience of Pleasure Scale (TEPS) Consummatory Pleasure score with 17-β estradiol versus placebo
The TEPS Consummatory Pleasure scale specifically captures sensory, physical, or immediate emotional gratification. It consists of 8 self-report items out of the 18 total items on the TEPS scale. Participants rate each of the 8 consummatory items using a 6-point Likert scale. To generate the final Consummatory Pleasure score, the raw values of the 8 items are summed and then averaged. The final score ranges between 1.0 and 6.0 range. Higher scores indicate greater capacity for pleasure. Lower scores indicate anhedonic traits.
Time frame: Baseline to 8 weeks
Change in delay discounting parameter k using the Monetary Choice Questionnaire with 17-β estradiol versus placebo
In this computerized task/verbal administration of the MCQ, we assess an individual's extent of discounting the value of future rewards with increasing delay to reward receipt. Subjects will make 27 binary choices between smaller immediate and larger delayed monetary rewards of varying value and delay to reward receipt. From their responses, their Delay Discounting Parameter k is Calculated. The parameter k serves as a direct proxy for behavioral impulsivity and delay tolerance. In the standard MCQ-27, the derived k values range from roughly 0.00016 (highly patient; willing to wait months for a marginally larger reward) to 0.25 (highly impulsive; completely unwilling to wait). Raw k values are heavily skewed to the right and violate normal distribution assumptions required for parametric statistics; thus, raw k parameters are normalized using a log-transformation (natural log ln) before running inferential statistics.
Time frame: Baseline to 8 weeks
Change in Eating Disorder Inventory-3 (EDI-3) Body Dissatisfaction score with 17-β estradiol versus placebo
The Body Dissatisfaction (BD) consists of 10 self-report items out of the 91 total items on the EDI-3, isolating the perceptual-affective component of body image disturbance. Participants rate each of the 10 items on a 6-point Likert scale. Total raw scores range from 0-36. Higher values indicate more pronounced body dissatisfaction/worse outcome.
Time frame: Baseline to 12 weeks
Change in EDI-3 Drive for Thinness score with 17-β estradiol versus placebo
The Drive for Thinness (DT) scale consists of 7 self-report items out of the 91 total items on the EDI-3, isolating the obsessive preoccupation with weight, restrictive dieting, extreme desire to be thinner, and a psychological terror or intense fear of weight gain. Participants rate each of the 7 items on a 6-point Likert scale. Total raw scores range from 0-28. Higher values indicate more pronounced drive for thinness/worse outcome.
Time frame: Baseline to 12 weeks
Change in functional magnetic resonance imaging (fMRI) activation of the dorsolateral prefrontal cortex (DLPFC) and anterior cingulate cortex (ACC) during a task switching paradigm with 17-β estradiol versus placebo
Time frame: Baseline to 8 weeks
Change in fMRI activation of the ventromedial prefrontal cortex (VMPFC) and ventral striatum in response to reward receipt with 17-β estradiol versus placebo
Time frame: Baseline to 8 weeks
Change in fMRI activation of the VMPFC and ventral striatum during delay discounting with 17-β estradiol versus placebo
Time frame: Baseline to 8 weeks
Change in the Eating Disorder Examination (EDE) Dietary Restraint subscale with 17-β estradiol versus placebo
The Dietary Restraint subscale consists of 5 items of the total 22 items rated on a forced-choice 7-point Likert scale ranging from 0 to 6 (0 = 0 days; 1 = 1-5 days; 2 = 6-12 days; 3 = 13-15 days; 4 = 16-22 days; 5 = 23-27 days; 6 = 28 days), targeting behavioral intentions and explicit attempts to restrict caloric intake over the past 28 days. Total score for the subscale is calculated by taking the average of the 5 constituent item scores. Total scores range from 0-6. Higher values indicate more pronounced dietary restraint/worse outcome.
Time frame: Baseline to 12 weeks
Change in caloric intake by 4-day food diary with 17-β estradiol versus placebo
The 4-day food diary (4DFR) captures detailed self-report food intake and includes 3 weekdays and 1 weekend day. Records will be analyzed by dieticians in the Clinical Research Center using NDS-R software v2008 (Nutrition Coordinating Center (NCC), University of Minnesota, Minneapolis, MN. The mean caloric intake over 4 days was calculated by summing the caloric intake each day of the 4 days and taking the average.
Time frame: Baseline to 12 weeks
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2019 to primary completion in Dec 2025, 78 months.
Completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → Dec 2025, on Nov 5, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Progesterone
Feeding and Eating Disorders →
Massachusetts General Hospital →